In Allergan Inc. v. Merz Pharmaceuticals LLC et al., Central District of California Judge Andrew J. Guilford barred Botox competitor, Merz Pharmaceuticals LLC, from selling wrinkle-reducing drug Xeomin. Botox maker, Allergan Inc., filed the case accusing seven of its former employees and Merz, of misappropriating trade secrets and violating the Lanham Act. In its suit, Allergan claimed that the former Allergan sales staff who left to join Merz pilfered customer ordering information and spreadsheets with details about approximately 24,000 Botox customers in the U.S. Merz claims that the information that was taken was either publicly available or posed no threat to Allergan. The court issued an order after closing arguments in court, with the final written order to follow setting out the terms and duration of the injunction.